Log in

PerkinElmer Stock Forecast, Price & News

+3.76 (+2.72 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $141.78
50-Day Range
MA: $129.79
52-Week Range
Now: $141.78
Volume750,263 shs
Average Volume913,755 shs
Market Capitalization$15.88 billion
P/E Ratio53.91
Dividend Yield0.20%
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
PerkinElmer logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services



Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$7.27 per share
Book Value$25.33 per share


Net Income$227.56 million


Market Cap$15.88 billion
Next Earnings Date1/25/2021 (Estimated)
+3.76 (+2.72 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PerkinElmer (NYSE:PKI) Frequently Asked Questions

How has PerkinElmer's stock been impacted by COVID-19 (Coronavirus)?

PerkinElmer's stock was trading at $72.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PKI stock has increased by 94.6% and is now trading at $141.78.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of PerkinElmer?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PerkinElmer
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PerkinElmer?

Wall Street analysts have given PerkinElmer a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PerkinElmer wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release its next quarterly earnings announcement on Monday, January 25th 2021.
View our earnings forecast for PerkinElmer

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) announced its earnings results on Wednesday, October, 28th. The medical research company reported $2.09 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.42 by $0.67. The medical research company had revenue of $964.03 million for the quarter. PerkinElmer had a return on equity of 18.40% and a net margin of 9.87%.
View PerkinElmer's earnings history

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer announced a quarterly dividend on Thursday, October 22nd. Stockholders of record on Friday, January 22nd will be given a dividend of $0.07 per share on Friday, February 12th. This represents a $0.28 annualized dividend and a yield of 0.20%. The ex-dividend date of this dividend is Thursday, January 21st.
View PerkinElmer's dividend history

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its fourth quarter earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $2.60-3.00 for the period, compared to the Thomson Reuters consensus estimate of $1.87. The company issued revenue guidance of $1.12-1.23 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for PKI?

14 brokers have issued 1-year price targets for PerkinElmer's stock. Their forecasts range from $45.00 to $193.00. On average, they anticipate PerkinElmer's stock price to reach $116.53 in the next year. This suggests that the stock has a possible downside of 17.8%.
View analysts' price targets for PerkinElmer

Are investors shorting PerkinElmer?

PerkinElmer saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,510,000 shares, an increase of 35.0% from the October 31st total of 2,600,000 shares. Based on an average daily trading volume, of 936,600 shares, the short-interest ratio is currently 3.7 days.
View PerkinElmer's Short Interest

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), The Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the following people:
  • Dr. Prahlad R. Singh Ph.D., CEO, Pres & Director (Age 55, Pay $1.84M)
  • Mr. James M. Mock, Sr. VP & CFO (Age 43, Pay $901.44k)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 51, Pay $1.75M)
  • Mr. Robert Francis Friel, Advisor (Age 64, Pay $6.9M)
  • Mr. Tajinder Vohra, Sr. VP of Global Operations (Age 54)
  • Mr. Andrew Okun, VP & Chief Accounting Officer (Age 50)
  • Mr. Bryan Kipp, VP of Investor Relations
  • Mr. Daniel R. Tereau, Sr. VP of Strategy & Bus. Devel. (Age 52)
  • Mr. David C. Francisco, CFO of Human Health & Corp. Treasurer
  • Mr. John L. Healy, VP, Associate Gen. Counsel & Assistant Sec.

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.36%), State Street Corp (4.04%), Massachusetts Financial Services Co. MA (3.40%), Great West Life Assurance Co. Can (2.15%), King Luther Capital Management Corp (2.14%) and The Manufacturers Life Insurance Company (0.97%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James M Mock, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Peter Barrett and Prahlad R Singh.
View institutional ownership trends for PerkinElmer

Which major investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Prudential PLC, State Street Corp, Sector Gamma AS, Thrivent Financial for Lutherans, Charles Schwab Investment Management Inc., Robecosam AG, and Allianz Asset Management GmbH. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, and Peter Barrett.
View insider buying and selling activity for PerkinElmer

Which major investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Great West Life Assurance Co. Can, The Manufacturers Life Insurance Company, Acadian Asset Management LLC, AQR Capital Management LLC, Massachusetts Financial Services Co. MA, AXA S.A., PFM Health Sciences LP, and Ceredex Value Advisors LLC.
View insider buying and selling activity for PerkinElmer

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $141.78.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $15.88 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 13,000 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.